This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Septic Shock
and you are
over 18
years old
4
The primary goal of this phase is to monitor the long-term effects.
The treatment is already on the market.
Show me locations

The purpose

The purpose is to demonstrate that vasoreactivity of patients with septic shock evaluated with dose-response curve is diminished in septic shock and ameliorated by activated protein C (APC). This amelioration is correlated to decrease of inflammation, decrease of reactive oxygen species (ROS) markers and increase of circulating catecholamines.

Provided treatments

  • Drug: Recombinant Activated Protein C
  • Device: Near-infrared spectroscopy (NIRS)
  • Drug: Phenylephrine
  • Biological: Blood sample

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02885168. The sponsor of the trial is Central Hospital, Nancy, France and it is looking for 30 volunteers for the current phase.
Official trial title:
Modulation of Vasoreactivity in Septic Shock: Impact of Recombinant Protein C